Background and Objectives：Passive smoking increases the risk of cardiovascular disease, but the factors responsible for this association remain largely unknown. We sought to determine whether passive smoke exposure is associated with systemic inflammation in a dose-dependent fashion, which is a known risk factor for cardiovascular events. Subjects and Methods：We analyzed the data of self-reported non-smokers, ≥40 years of age, who were from the Third National Health and Nutrition Examination Survey (n=6,595). We quantified the passive nicotine exposure by dividing the non-smokers into quartiles, as based on the serum cotinine values. We used multiple linear and logistic regression models to determine the independent relationship between serum cotinine and the levels of C-reactive protein, fibrinogen and leukocytes, and the platelet expression. Results： After adjustments were done for age, gender, body mass index and race, the participants in the highest serum cotinine quartile (quartile 4) had circulating platelet, fibrinogen and homocysteine levels that were 6,893/μL higher (95% confidence interval [CI]: 1,886 to 11,900/μL, p=0.007), 8.74 mg/dL (95% CI: 2.63 to 14.84 mg/dL, p=0.005) and 0.90 μmol/L (95% CI: 0.36 to 1.43 (μmol/L, p=0.001), respectively, than in those in the lowest quartile of serum cotinine (quartile 1). There was a dose-dependent increase in the circulating fibrinogen, homocysteine and platelet levels across the quartiles of cotinine. Conclusion：These findings indicate that even among nonsmokers, elevated serum cotinine is an independent risk factor for systemic inflammation. This suggests that passive smoke exposure promotes systemic inflammatory response in a dose-dependent fashion. These observations may explain why passive smoking is a risk factor for atherosclerosis and cardiovascular events. (Korean Circulation J 2006;36:510-515)
Introduction
Nonsmokers who are exposed to passive smoking are at an increased risk for both fatal and nonfatal cardiac events. [1] [2] [3] In several large epidemiologic studies, the incremental risk of passive cigarette exposure on cardiovascular death has been reported to be -30%.
4) The biomarkers of passive exposure to smoking, particularly cotinine(a nicotine metabolite), can provide a summary measure of the exposure from all environmental sources 5) ; in the British regional heart study, Whincup and coworkers prospectively showed the positive associations between the serum cotinine concentration and risk of coronary heart disease(CHD) in non-smokers. 6) While the exact mechanism that is responsible for this observation is incompletely understood, several mechanisms have been proposed. [7] [8] [9] [10] Persistent lowgrade systemic inflammation is increasingly being thought to play an integral role in the pathogenesis of cardiovascular events, including plaque formation, rupture and subsequent atherothrombosis. 11) Whether passive smoking promotes systemic inflammation is not well known. Panagiotakos and coworkers 12) have showed that individuals who are exposed to second-hand smoke had higher circulating white blood cell counts, fibrinogen levels and C-reactive protein(CRP) levels than those subjects who were without such exposure. Another study has also reported similar associations. 13) However, all of these studies collected exposure data from self-reports; none of them used biochemical measurements to objectively quantify the intensity of exposure. Moreover, all of these studies were relatively small in size and scope and as such, they could not ascertain a dose-response relationship between the intensity of exposure and the burden of systemic inflammation among those subjects who were passively exposed to secondhand smoke. This information would be important for determining whether the inflammatory responses to secondhand smoke exposure are threshold-dependent or linear.
We used information that was collected from a large population-based survey as a representative sample of the general U.S. population, the Third National Health and Nutrition Examination Survey(NHANES III), to determine (1) whether passive smoke exposure is associated with increased circulating levels of CRP and other inflammatory markers; and (2) whether the intensity of the systemic inflammation is associated with the serum cotinine levels.
Subjects and Methods

Study design
The detailed methods for the NHANES III survey have been described previously. 14) Briefly, NHANES III was a cross-sectional, multistage probability sampling survey that was conducted between 1988 and 1994, and it was representative of the total non-institutionalized civilian population of the United States. The NHANES III data collection included a home interview and a detailed clinical examination that was conducted in a mobile examination center. "Ever smoking cigarettes" was defined by self-report of having smoked at least 100 cigarettes in a participant's lifetime. "Current cigarette smoking" was defined by answering "yes" to the question: "Do you smoke cigarettes now?" We defined subjects as being current, former or never smokers based on their responses to a series of questions. Our study sample was limited to 6,595 adults aged 40 years or older who were not current smokers, and they all had complete data available on the serum cotinine, and the fibrinogen and CRP levels.
Laboratory measurements
The laboratory procedures used in the NHANES III study are described elsewhere. 15) Briefly, the serum cotinine level was measured by performing high-performance liquid chromatography atmospheric-pressure chemical ionization tandem mass spectrometry. 16) We quantified the passive nicotine exposure by dividing the non-smokers into quartiles based on the serum cotinine values. For the dose-response analysis with using cotinine, quartile 1 was used as the reference category. The CRP level was measured by performing latexenhanced nephelometry. 15) Because 4,088(62%) of the participants had CRP values below the lowest detectable level(2.2 mg/L), for analytic purposes, CRP was treated as a categorical variable rather than as a continuous variable. The CRP levels ≥2.2 mg/L were considered "detectable," whereas levels >10.0 mg/L were categorized as "elevated."
17) The fibrinogen level was measured for all participants 40 years of age or older by using enzyme assay methods.
18) The serum homocysteine level was measured by performing highperformance liquid chromatography. 19) The homocysteine levels were collected between 1991 and 1994 (during phase 2 of the NHANES III study), and these were available for 3,143 participants for this analysis. We determined the leukocyte and platelet counts, and the levels of total serum cholesterol, high-density lipoprotein(HDL), low-density lipoprotein(LDL), triglyceride and lipoprotein(a).
Covariates
We classified age(in years) into quintiles: ≤47, 48 to 58, 59 to 67, 68 to 76 and ≥77. Race was divided into 3 categories: white, black and other. The smoking status was divided into 3 strata: the current, former and never smokers. We divided the body mass index (BMI in kg/m 2 ) into quintiles: ≤23.5, 23.6 to 26.0, 26.1 to 28.5, 28.6 to 31.8 and ≥31.9. The blood pressure was measured three times during the home interview and also three times during the clinical examination by using a standard mercury sphygmomanometer with the participant in a seated position. A participant's mean blood pressure was calculated by using all the available systolic and diastolic readings. The presence of co-morbidities was determined by the participants' responses to the question: "Has a doctor ever told you that you have diabetes(congestive heart failure, chronic bronchitis, etc)?" The participants were deemed to have rheumatoid arthritis or a related inflammatory disorder if they had a significantly elevated titer of rheumatoid factor(≥1：40) on a serum dilution latex fixation test.
20)
Statistical analyses
The baseline characteristics of the study participants that were within quartiles 2, 3 and 4 were compared with quartile 1 of cotinine with using a χ 2 test for the binary variables and using a t test for the continuous variables. To assess whether there was a gradient in the various baseline demographic and clinical factors across the quartiles for cotinine, we used a Mantel-Ha-enszel test for determining any trend. For Table 2 and Fig. 1 , we used multiple linear regression techniques to estimate the independent impact of cotinine on the circulating levels of leukocytes, platelets, fibrinogen and homocysteine. In Fig. 1 , we performed a weighted multiple linear regression analysis with one degree of freedom as a test for any trend. We used a multiple logistic modeling technique to determine whether the cotinine level was associated with elevations in the CRP levels (Table 3) . In all these models, we forced in age, gender, BMI and race to adjust for their potential effects on systematic inflammation. All the tests were 2-tailed in nature. Continuous variables are shown as means±SD, unless otherwise indicated.
Results
There were 6,595 participants in this analysis(45.3% were males and 75.6% were white). The average age and BMI of the participants were 62.3±0.2 years and 27.9±0.1 kg/m 2 , respectively. The baseline characteristics and laboratory profiles, as divided into quartiles of cotinine, are summarized in Table 1 . The male gender, being an ex-smoker and BMI were positive risk factors for higher cotinine levels, whereas age and the white race were inversely correlated with the cotinine levels. Compared with the controls, the systolic blood pressure was 3.5 mmHg(95% CI: 2.1 to 5.1) and 2.3 mmHg(95% CI: 1.1 to 4.2) lower and the diastolic blood pressure was 1.9 mmHg(95% CI: 0.6 to 2.1) and 2.6 mmHg(95% CI: 1.9 to 3.5) higher in those subjects within quartile 3 and 4, respectively. Diabetes and congestive heart failure were significantly lower among the participants within the quartile 3 and 4 than among the controls, but thyroid disease, rheumatoid arthritis and the fasting glucose levels were similar across the quartile groups of cotinine.
There were no significant differences in the circulating levels of CRP, fibrinogen, and homocysteine across the quartile groups of cotinine, and the circulating levels of platelets were higher in the participants who were within quartile 4; the leukocyte count was lower in those subjects within quartile 3. The lipid profiles among the 4 groups are also shown in Table 1 . There were no significant differences in the total cholesterol, LDL cholesterol, triglyceride or HDL cholesterol concentrations among the groups. The participants within quartile 4 had higher serum concentrations of lipoprotein(a), as compare with the controls.
Relationship between the serum cotinine levels and the inflammatory markers.
The Beta coefficients and 95% Confidence Intervals(CIs) for the fibrinogen, homocysteine, leukocyte and platelet levels are presented in Table 2 . After adjustments for age, sex, BMI and race, the participants in the highest serum cotinine quartile(quartile 4) had circulating platelet, fibrinogen and homocysteine levels of 6,893/μL(95% confidence interval [CI]: 1,886 to 11,900/μL, p=0.007), 8.74 mg/dL (95% CI: 2.63 to 14.84 mg/dL, p=0.005) and 0.90 μmol/L(95% CI: 0.36 to 1.43 μmol/L, p=0.001); these were higher, respectively, than in those of the subjects in the lowest quartile of serum cotinine(quartile 1). In Fig. 1 , there was a dose-dependent increase in the circulating fibrinogen, homocysteine and platelet levels across the quartiles of cotinine. No association was detected between cotinine and the leukocytes. Table 3 shows the odds ratios and the 95% CIs for the detectable and clinically elevated CRP levels by the quartile groups of cotinine. No interaction was present for the association between cotinine and CRP in the detectable or clinically elevated ranges after adjusting for age, gender, BMI and race.
Discussion
Using a large representative sample of the U.S. population, this study identified a positive, independent and dose-response relationship between the serum cotinine levels and several inflammatory risk factors in nonsmokers. Although there were small differences for the cotinine levels, the fibrinogen, homocysteine and platelet levels showed significantly positive linear trends across the quartile group after adjustments were made for for age, gender, BMI and race. Our results suggest that environmental tobacco exposure may result in chronic low grade inflammation with increased levels of several inflammation markers, as is seen among the active smokers. 21) Serum fibrinogen may promote hemostasis by increasing blood viscosity and acting as a cofactor for platelet aggregation.
11) Increased levels of homocysteine have also been implicated in the pathogenesis of atherosclerosis. 22) Our observations may provide one of the potential mechanisms for those findings of Whincup et al 6) ; they showed the positive associations between the cotinine concentration and coronary heart disease among nonsmokers. They revealed that the risks in the upper three cotinine groups were higher than the risk in the lowest group, and the association between the cotinine concentration and CHD seemed to be graded. They did not evaluate the role of systemic inflammation on the risk of CHD. Although there were significant differences of the cotinine levels across the quarters of the cotinine distribution between the two studies, we have shown a linear increase in circulating levels of inflammatory markers across the quartiles of cotinine. This suggests that passive smoke exposure promotes a systemic inflammatory response in a dose-dependent fashion.
This study has several strengths, but it also has some limitations. The study's first strength is that it was conducted on a nationally representative sample; therefore, the results can be generalized to the entire U.S. population. Second, we used a reliable biochemical marker of tobacco use, the serum cotinine level.
5) The level of cotinine enhances our understanding of the relationship between recent short-term passive smoke exposure and the inflammatory risk factors. It is important to note that some of the cardiovascular effects occur very quickly, and some occur within minutes after breathing secondhand smoke. Endothelial dysfunction, 23) abnormal platelet function, 2) oxidation of LDL, 24) increases in the circulating white blood cell counts, 25) and decreased heart rate variability 26) showed rapid responses and they are compromised to a level similar to what is observed in a regular smoker. A study using cotinine would be desirable to know if other inflammatory markers such as CRP, fibrinogen, and homocysteine respond as quickly to passive smoking and how long it takes for the effect to resolve after the exposure ends.
Several limitations of this study should be emphasized. The first limitation of the current study is its cross-sectional design, which didn't allow us to determine the temporal relationship between cigarette smoking and the elevation of novel risk factors. The second limitation of our analysis is the fact that the NHANES III survey was conducted between 1988 and 1994, and this was before a high-sensitivity assay for CRP became widely available. Therefore, 62% of the cohort in this study was categorized as having undetectable CRP levels(<2.2 mg/L). Consequently, we could not examine the relationship between cotinine and the CRP levels as a continuous variable. Our study could not determine the relationship between cotinine and CRP, but a recent study using a highly sensitivity assay showed that CRP was significantly higher in the never smokers who reported regular exposure to second-hand smoke than in the never smokers who were not exposed to secondhand smoke. 12) Future work is needed to determine the association between the cotinine concentration and the highly sensitivity CRP levels in non-smokers.
Another limitation is that our study included 593 participants of the former and never smokers who had a serum cotinine level of 10 ng/mL or higher. Measurement of cotinine may reduce the misclassification among self-reported nonsmokers in epidemiologic studies.
5) The higher misclassification rate for reported ex-smokers(more than double that of the reported never smokers) was expected since deceptive reporting is known to be a more frequent problem among this group. 27) Previous studies have used a range of the serum cotinine level(10-15 ng/mL) as a cutoff point for discriminating between the current smokers and the nonsmokers. [27] [28] [29] In conclusion, these findings indicate that even among nonsmokers, elevated serum cotinine is an independent risk factor for systemic inflammation. This suggests that passive smoke exposure promotes a systemic inflammatory response in a dose-dependent fashion. These observations may explain why passive smoking is a risk factor for atherosclerosis and cardiovascular events.
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